Title

Dronedarone.

Authors

Chinmay Patel, Main Line Health Heart CenterFollow
Gan-Xin Yan, Main Line Health Heart Center; Jefferson Medical College, Thomas Jefferson University; Lankenau Institute for Medical ResearchFollow
Peter R Kowey, Main Line Health Heart Center; Jefferson Medical College, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

8-18-2009

Comments

This article has been peer reviewed and is published in Circulation 2009 Aug 18;120(7):636-44. The published version is available at DOI: 10.1161/CIRCULATIONAHA.109.858027. ©American Heart Association

Abstract

Amiodarone is the most effective antiarrhythmic drug for maintaining sinus rhythm for patients with atrial fibrillation. Extra-cardiac side effects have been a limiting factor, especially during chronic use, and may offset its benefits. Dronedarone is a noniodinated benzofuran derivative of amiodarone that has been developed for the treatment of atrial fibrillation and atrial flutter. Similar to amiodarone, dronedarone is a potent blocker of multiple ion currents, including the rapidly activating delayed-rectifier potassium current, the slowly activating delayed-rectifier potassium current, the inward rectifier potassium current, the acetylcholine activated potassium current, peak sodium current, and L-type calcium current, and exhibits antiadrenergic effects. It has been studied for maintenance of sinus rhythm and control of ventricular response during episodes of atrial fibrillation. Dronedarone reduces mortality and morbidity in patients with high-risk atrial fibrillation, but may be unsafe in those with severe heart failure. This article will review evidence of safety and effectiveness of dronedarone in patients with atrial fibrillation.

Recommended Citation

Patel, Chinmay; Yan, Gan-Xin; and Kowey, Peter R, "Dronedarone." (2009). Department of Medical Genetics Faculty Papers. Paper 1.
https://jdc.jefferson.edu/medgenfp/1

PubMed ID

19687370